上海谊众2025年归属净利润6413.2万元，同比增长819.42%

Core Insights - Shanghai Yizhong (688091) reported a significant increase in revenue and profit for 2025, with total revenue reaching 317 million yuan, representing a year-on-year growth of 82.72% [1] - The net profit attributable to shareholders was 64.132 million yuan, showing an impressive year-on-year increase of 819.42% [1] - The company's core product, injectable paclitaxel polymer micelles, was officially included in the national medical insurance directory in 2025, which greatly enhanced market access and the number of patients using the product, driving revenue and profit growth for the year [1]